Option chain shows key data for Elite Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Elite Pharmaceuticals.

Elite Pharmaceuticals (OTC:ELTP) Stock, Option Chain

Elite Pharmaceuticals

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Earnings

News

Pre-Market Outlook

Markets

CMCM

ELTP

MMMB

SHIP

Earnings Scheduled For June 14, 2019

ELITE PHARMS INC by Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Inc

<p>Elite Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELTP#OTC">ELTP</a>) reported quarterly losses of $(0.01) per share.  The company reported $14.36 million in sales this quarter. This is a 7.56 percent decrease over sales of $15.54 million the same period last year.</p>


Elite Pharmaceuticals Q3 EPS $(0.01), Sales $14.36M Down From $15.54M YoY

<p>Elite Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELTP#OTC">ELTP</a>) reported $8.98 million in sales this quarter. This is a 17.03 percent increase over sales of $7.67 million the same period last year.</p>


Elite Pharmaceuticals Q1 Sales $8.98M Up From $7.67M YoY

<p>Elite Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELTP#OTC">ELTP</a>) reported $9.25 million in sales this quarter. This is a 3.06 percent increase over sales of $8.97 million the same period last year.</p>


Elite Pharmaceuticals Q3 Sales $9.25M Up From $8.97M YoY

<h3>Companies Reporting Before The Bell</h3>
<p>&bull; Just Energy Group Inc. (NYSE:<a class="ticker" href="/stock/JE#NYSE">JE</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $873.77 million.</p>
<p>&bull; Jerash Holdings (US) Inc. (NASDAQ:<a class="ticker" href="/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $16.90 million.</p>
<p>&bull; China XD Plastics Co Inc. (NASDAQ:<a class="ticker" href="/stock/CXDC#NASDAQ">CXDC</a>) is expected to report earnings for its first quarter.</p>
<h3>&nbsp;</h3>
<h3>Companies Reporting After The Bell</h3>
<p>&bull; Micron Technology Inc. (NASDAQ:<a class="ticker" href="/stock/MU#NASDAQ">MU</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $5.31 billion.</p>
<p>&bull; Herman Miller Inc. (NASDAQ:<a class="ticker" href="/stock/MLHR#NASDAQ">MLHR</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $479.63 million.</p>
<p>&bull; Global Cord Blood Inc. (NYSE:<a class="ticker" href="/stock/CO#NYSE">CO</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $39.36 million.</p>
<p>&bull; Elite Pharmaceuticals Inc. (OTC:<a class="ticker" href="/stock/ELTP#OTC">ELTP</a>) is estimated to report earnings for it&#39;s fourth quarter.<br />
&nbsp;</p>


CXDC

JRSH

MLHR

Earnings Scheduled For June 29, 2020

Intraday Update

Movers

Trading Ideas

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALFVY

ALIAF

ALIF

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANACONDA MINING INC by Anaconda Mining Inc.

ANXGF

Australia and New Zealand Banking Group Limited

ANZBY

ANZLY

AOIFF

AOMFF

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARKAY

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

<h3>Companies Reporting Before The Bell</h3>
<ul>
<li><strong>Cheetah Mobile Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmcm#NYSE">CMCM</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $155.06 million.</li>
<li><strong>MamaMancini&#39;s Holdings, Inc. </strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmmb#OTC">MMMB</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $7.22 million.</li>
<li><strong>China Online Education Group</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coe#NYSE">COE</a>) is estimated to report earnings for its first quarter.</li>
</ul>
<p>&nbsp;</p>
<h3>Companies Reporting After The Bell</h3>
<ul>
<li><strong>Seanergy Maritime Holdings Corp. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ship#NASDAQ">SHIP</a>) is expected to post quarterly loss at $2.85 per share on revenue of $12.29 million.</li>
<li><strong>Elite Pharmaceuticals, Inc. </strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/eltp#OTC">ELTP</a>) is estimated to post earnings for its fourth quarter.</li>
</ul>


Elite Pharma Launches Generic Hydroxyziine Tablets, Completes Dosing For Two ELI-200 Studies

<p> Elite Pharmaceuticals, Inc. ("Elite") (OTCBB: ELTP) announced today that on January 23, 2012, the U.S. Food and Drug Administration approved the Company's supplemental application for the manufacturing and packaging of Hydromorphone Hydrochloride USP 8 mg. This approval will allow the Company to commence the commercial manufacturing and packaging of this product for its sales and marketing partner, which will distribute the product as part of a multi-product distribution agreement.</p>

<p>Hydromorphone hydrochloride is a member of the opioid analgesic and antitussive class. It is a pure opioid agonist used primarily for pain relief or as a cough suppressant. For the twelve months ending September 2011, Dilaudid® 8 mg tablets and its generic equivalents had total U.S. sales of approximately $30 million according to IMS Health Data.
</p>

Elite Pharmaceuticals Announces FDA Approval of Supplemental Application for Hydromorphone  

Press Releases

Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets

Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information

Comments

Elite Pharmaceuticals

Elite Pharmaceuticals (ELTP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga